tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Leukemia D007938 74 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Hematoma D006406 5 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Lymphoproliferative Disorders D008232 7 associated lipids
Crohn Disease D003424 12 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Cholestasis D002779 23 associated lipids
Fibrosis D005355 23 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
Thyroid Diseases D013959 8 associated lipids
Sinusitis D012852 9 associated lipids
Leukocytosis D007964 9 associated lipids
Glomerulonephritis D005921 35 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Hypoglycemia D007003 13 associated lipids
Hemolytic-Uremic Syndrome D006463 2 associated lipids
Pancytopenia D010198 6 associated lipids
Nervous System Diseases D009422 37 associated lipids
Ataxia D001259 20 associated lipids
Psoriasis D011565 47 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Brain Edema D001929 20 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Respiratory Insufficiency D012131 10 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Erectile Dysfunction D007172 19 associated lipids
Gingivitis D005891 3 associated lipids
Periodontal Pocket D010514 9 associated lipids
Brain Infarction D020520 17 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Stroke D020521 32 associated lipids
Liver Cirrhosis, Biliary D008105 12 associated lipids
Hyperbilirubinemia D006932 11 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Nephritis, Interstitial D009395 10 associated lipids
Nephrotic Syndrome D009404 11 associated lipids
Brain Ischemia D002545 89 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Ischemia D007511 18 associated lipids
Glycosuria D006029 10 associated lipids
Seizures D012640 87 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Nerve Degeneration D009410 53 associated lipids
Peptic Ulcer D010437 19 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Morris-Stiff G et al. Immunosuppression in renal transplantation. Meta-analysis should not have included one of the studies. 1999 BMJ pmid:10531121
Williams H New treatments for atopic dermatitis. 2002 BMJ pmid:12089073
Allen BR and Luger TA Risk: benefit ratio is important in treating atopic dermatitis. 2002 BMJ pmid:12399360
Misra DP et al. Pulmonary co-infection with Nocardia and Aspergillus in a patient with adult-onset Still's disease receiving steroids and tacrolimus. 2014 BMJ Case Rep pmid:25398925
Slocum AMY A surgeon's nightmare: pyoderma gangrenosum with pathergy effect mimicking necrotising fasciitis. 2017 BMJ Case Rep pmid:29269363
Maus EA The importance of challenging your diagnosis even in straightforward cases. 2012 BMJ Case Rep pmid:22847565
Mallon DH et al. A spontaneous coronary arterial dissection associated with a calcineurin inhibitor. 2012 BMJ Case Rep pmid:22783013
Borges-Costa J et al. Kaposi's sarcoma presenting as violaceous macules on the chest of a kidney transplanted patient. 2016 BMJ Case Rep pmid:26759393
Bonanni A et al. Low-dose ofatumumab for rituximab-resistant nephrotic syndrome. 2015 BMJ Case Rep pmid:26376698
Wu G et al. Tacrolimus-induced encephalopathy and polyneuropathy in a renal transplant recipient. 2013 BMJ Case Rep pmid:24311415
Purani JM and Purani HJ Treatment of geographic tongue with topical tacrolimus. 2014 BMJ Case Rep pmid:25085945
Viecelli A et al. Diagnostic and management dilemma of a pancreas-kidney transplant recipient with aplastic anaemia. 2014 BMJ Case Rep pmid:25257886
Kirpalani A et al. Idiosyncratic drug reactions and membranous glomerulopathy. 2017 BMJ Case Rep pmid:28137906
Liu HY et al. Ribavirin-induced anaemia reduced tacrolimus level in a hepatitis C patient receiving haemodialysis. 2018 BMJ Case Rep pmid:29669765
Gupta M et al. Tacrolimus-induced unilateral ischaemic optic neuropathy in a non-transplant patient. 2012 BMJ Case Rep pmid:22914240
Krystel-Whittemore M et al. Polyomavirus nephropathy of the native kidney in a patient with rheumatoid arthritis and pulmonary fibrosis. 2015 BMJ Case Rep pmid:26318171
Boyer NL et al. Tacrolimus-associated thrombotic microangiopathy in a lung transplant recipient. 2013 BMJ Case Rep pmid:23396921
Undre N and Dickinson J Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants. 2017 BMJ Open pmid:28377389
Goldsmith PM et al. Impact of intrapatient variability (IPV) in tacrolimus trough levels on long-term renal transplant function: multicentre collaborative retrospective cohort study protocol. 2017 BMJ Open pmid:28756385
Castillo Lugo JA Clinical and experimental immunosuppression. 1995 May-Jun Bol Asoc Med P R pmid:8573248
Varanasi SS and Datta HK Characterisation of cytosolic FK506 binding protein 12 and its role in modulating expression of Cbfa1 and osterix in ROS 17/2.8 cells. 2005 Bone pmid:15780950
Fukunaga J et al. Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506. 2004 Bone pmid:15003790
Darcy A et al. A novel library screen identifies immunosuppressors that promote osteoblast differentiation. 2012 Bone pmid:22421346
Voggenreiter G et al. Immunosuppression with FK506 has no influence on fracture healing in the rat. 2005 Bone pmid:15963777
Igarashi K et al. Cyclosporine A and FK506 induce osteoclast apoptosis in mouse bone marrow cell cultures. 2004 Bone pmid:15207740
Velasco-Guardado A et al. Potential protective effect of Helicobacter pylori on the development of gastrointestinal GvHD. 2016 Bone Marrow Transplant. pmid:26950379
Kharfan-Dabaja MA et al. Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation. 2017 Bone Marrow Transplant. pmid:27819684
Cutler C et al. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. 2011 Bone Marrow Transplant. pmid:20697368
Parody R et al. GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study. 2016 Bone Marrow Transplant. pmid:27295268
Hale GA et al. Blood tacrolimus concentrations in bone marrow transplant patients undergoing plasmapheresis. 2000 Bone Marrow Transplant. pmid:10723590
Rotenstein L et al. Management of refractory autoimmune hemolytic anemia via allogeneic stem cell transplantation. 2016 Bone Marrow Transplant. pmid:27272445
Schmook T et al. Treatment of cutaneous chronic graft-versus-host disease with topical pimecrolimus. 2005 Bone Marrow Transplant. pmid:15895116
Ali H et al. Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus. 2015 Bone Marrow Transplant. pmid:25365064
Labrador J et al. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus. 2014 Bone Marrow Transplant. pmid:24566710
Wingard JR et al. Lack of interaction between tacrolimus (FK506) and methotrexate in bone marrow transplant recipients. 1997 Bone Marrow Transplant. pmid:9232256
Tam PM et al. Topical 0.03% tacrolimus ointment in the management of ocular surface inflammation in chronic GVHD. 2010 Bone Marrow Transplant. pmid:19802037
Misawa A et al. FK506-induced intractable leukoencephalopathy following allogeneic bone marrow transplantation. 2000 Bone Marrow Transplant. pmid:10673708
Przepiorka D et al. Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated donor cord blood transplantation. 1999 Bone Marrow Transplant. pmid:10414918
Okano A et al. Subcutaneous infection with Mycobacterium fortuitum after allogeneic bone marrow transplantation. 2001 Bone Marrow Transplant. pmid:11704796
Parody R et al. GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT. 2015 Bone Marrow Transplant. pmid:25310306
Kanda Y et al. A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation. 2016 Bone Marrow Transplant. pmid:26437063
Takahata M et al. Cyclosporin A-induced encephalopathy after allogeneic bone marrow transplantation with prevention of graft-versus-host disease by tacrolimus. 2001 Bone Marrow Transplant. pmid:11704797
Espino G et al. Assessment of myocardial hypertrophy by echocardiography in adult patients receiving tacrolimus or cyclosporine therapy for prevention of acute GVHD. 2001 Bone Marrow Transplant. pmid:11803349
Watanabe N et al. Relationship between tacrolimus blood concentrations and clinical outcome during the first 4 weeks after SCT in children. 2010 Bone Marrow Transplant. pmid:19915626
Uberti JP et al. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies. 1997 Bone Marrow Transplant. pmid:9208118
Ohashi Y et al. Successful treatment of steroid-resistant severe acute GVHD with 24-h continuous infusion of FK506. 1997 Bone Marrow Transplant. pmid:9085743
Ratanatharathorn V et al. Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT. 2015 Bone Marrow Transplant. pmid:25285804
Kato H et al. Significant improvement of Takayasu arteritis after cord blood transplantation in a patient with myelodysplastic syndrome. 2014 Bone Marrow Transplant. pmid:24317130
Furlong T et al. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. 2000 Bone Marrow Transplant. pmid:11100278
Narimatsu H et al. Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults. 2007 Bone Marrow Transplant. pmid:17115066
Lekakis L et al. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. 2006 Bone Marrow Transplant. pmid:16892072
Ikegame K et al. Successful treatment of bcr/abl-positive acute mixed lineage leukemia by unmanipulated bone marrow transplantation from an HLA-haploidentical (3-antigen-mismatched) cousin. 2003 Bone Marrow Transplant. pmid:12796797
Przepiorka D et al. Tacrolimus clearance is age-dependent within the pediatric population. 2000 Bone Marrow Transplant. pmid:11041564
Ganetsky A et al. Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation. 2016 Bone Marrow Transplant. pmid:26691423
Woo M et al. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation. 1997 Bone Marrow Transplant. pmid:9466284
Jabbour E et al. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. 2007 Bone Marrow Transplant. pmid:17603511
Honda A et al. Omission of day-11 MTX, in combination with tacrolimus, is not associated with increased risk of acute graft-versus-host disease after allo-BMT. 2013 Bone Marrow Transplant. pmid:22751000
Ram R et al. Prophylaxis regimens for GVHD: systematic review and meta-analysis. 2009 Bone Marrow Transplant. pmid:18997826
Neuman DL et al. Toxic absorption of tacrolimus [corrected] in a patient with severe acute graft-versus-host disease. 2005 Bone Marrow Transplant. pmid:16151424
Khimani F et al. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention. 2017 Bone Marrow Transplant. pmid:28368376
Fuji S et al. Decreased insulin secretion in patients receiving tacrolimus as GVHD prophylaxis after allogeneic hematopoietic SCT. 2010 Bone Marrow Transplant. pmid:19648969
Skeens M et al. Twice daily i.v. bolus tacrolimus infusion for GVHD prophylaxis in children undergoing stem cell transplantation. 2012 Bone Marrow Transplant. pmid:22484323
Hiraoka A et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. 2001 Bone Marrow Transplant. pmid:11509936
Yu C et al. Glucocorticoids fail to enhance the effect of FK506 and methotrexate in prevention of graft-versus-host disease after DLA-nonidentical, unrelated marrow transplantation. 1997 Bone Marrow Transplant. pmid:9244417
Kakihana K et al. Clinical features of calcineurin inhibitor-induced pain syndrome after allo-SCT. 2012 Bone Marrow Transplant. pmid:21625227
Yoshida Y et al. FK506-associated limbic injury following umbilical cord blood transplantation. 2003 Bone Marrow Transplant. pmid:12942100
Gaziev D et al. Chronic graft-versus-host disease: is there an alternative to the conventional treatment? 2000 Bone Marrow Transplant. pmid:10745252
Mori T et al. Drug interaction between voriconazole and tacrolimus in allogeneic hematopoietic SCT recipients. 2011 Bone Marrow Transplant. pmid:20453893
Seropian S et al. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma. 2003 Bone Marrow Transplant. pmid:14520419
Kanamaru A et al. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. 1995 Bone Marrow Transplant. pmid:7581086
Koehler MT et al. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation. 1995 Bone Marrow Transplant. pmid:7581088
Riley L et al. Cross-sensitivity reaction between tacrolimus and macrolide antibiotics. 2000 Bone Marrow Transplant. pmid:10808214
Jacobson P et al. Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. 1998 Bone Marrow Transplant. pmid:9720734
Hsiao CC et al. Evaluation for synergistic suppression of T cell responses to minor histocompatibility antigens by chloroquine in combination with tacrolimus and a rapamycin derivative, SDZ-RAD. 2002 Bone Marrow Transplant. pmid:12476284
Najera JE et al. Akinetic mutism-a serious complication to tacrolimus-based GVHD prophylaxis. 2013 Bone Marrow Transplant. pmid:22705799
Devine SM et al. Tacrolimus (FK506)-induced cerebral blindness following bone marrow transplantation. 1996 Bone Marrow Transplant. pmid:8879619
Przepiorka D et al. Bronchiolitis obliterans organizing pneumonia in a BMT patient receiving FK506. 1993 Bone Marrow Transplant. pmid:7687503
Trifilio SM et al. Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring. 2010 Bone Marrow Transplant. pmid:19966844
Przepiorka D et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. 1999 Bone Marrow Transplant. pmid:10516680
Gondo H et al. Acquired Pelger-Huët anomaly in association with concomitant tacrolimus and fluconazole therapy following allogeneic bone marrow transplantation. 2000 Bone Marrow Transplant. pmid:11149744
Couriel DR et al. Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation. 2002 Bone Marrow Transplant. pmid:12379897
Yu C et al. Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation. 1996 Bone Marrow Transplant. pmid:8722370
Mori T et al. Cold agglutinin disease associated with adenovirus infection after allogeneic bone marrow transplantation. 2005 Bone Marrow Transplant. pmid:15937504
Suehiro A et al. Enhancement by cyclosporine A and tacrolimus of serotonin-induced formation of small platelet aggregation. 2002 Bone Marrow Transplant. pmid:11850703
Uberti JP et al. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes. 2004 Bone Marrow Transplant. pmid:15273705
Sastry J et al. Acute pancreatitis due to tacrolimus in a case of allogeneic bone marrow transplantation. 2004 Bone Marrow Transplant. pmid:14743193
Han CW et al. Differential effects of the immunosuppressants cyclosporin A, FK506 and KM2210 on cytokine gene expression. 1995 Bone Marrow Transplant. pmid:7545487
Castagna L et al. Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide. 2016 Bone Marrow Transplant. pmid:26595078
Mookerjee B et al. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. 1999 Bone Marrow Transplant. pmid:10482936
Prot-Labarthe S et al. Toxic serum levels of tacrolimus after topical administration in an infant with severe cutaneous graft-versus-host disease. 2007 Bone Marrow Transplant. pmid:17549052
Yanagisawa R et al. Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT. 2011 Bone Marrow Transplant. pmid:20383212
Shayani S et al. Aprepitant (Emend) significantly increases sirolimus levels in patients undergoing allogeneic hematopoietic SCT. 2012 Bone Marrow Transplant. pmid:21383680
Zohren F et al. Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases. 2011 Bone Marrow Transplant. pmid:20661230
Dvorak CC et al. Use of intravenous mycophenolate mofetil for graft-versus-host disease prophylaxis in an allogeneic hematopoietic stem cell transplant recipient with an allergic reaction to cyclosporine and tacrolimus. 2006 Bone Marrow Transplant. pmid:16785867
Trede NS et al. Tacrolimus (FK506) in allogeneic bone marrow transplantation for severe aplastic anemia following orthotopic liver transplantation. 1997 Bone Marrow Transplant. pmid:9257897
Khaled SK et al. A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant. 2013 Bone Marrow Transplant. pmid:23000644
Nieto Y et al. Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation. 2000 Bone Marrow Transplant. pmid:10918414
Yanik G et al. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation. 2000 Bone Marrow Transplant. pmid:10918426
Cooper MH et al. Short-term myeloid reconstitution following TBI is not adversely affected by doses of FK506 that abrogate lethal GVHD. 1994 Bone Marrow Transplant. pmid:7527689
Al-Kadhimi Z et al. Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention. 2017 Bone Marrow Transplant. pmid:28581472